DÜSSELDORF, Germany, February 9 /PRNewswire/ -- Chief Executive Officer Dr. Axel Herberg (51) is not seeking reappointment and will leave the Management Board when his contract expires in June. The Supervisory Board has received this decision with regret and in its meeting today appointed as Herberg's successor from June the Management Board member of many years' standing, Uwe Röhrhoff (47).
Herberg looks back over almost twenty years in top management with Gerresheimer. Particularly in his ten years as CEO, he has shaped the Düsseldorf company's development into an internationally leading supplier to the pharma and healthcare industry and was also instrumental in the successful flotation of Gerresheimer AG, which is now listed on the M-Dax. Herberg has worked side by side with his successor in a relationship of mutual trust for many years. Röhrhoff stands for continuity and experience at the top of the business and has already been with Gerresheimer for twenty years. He was appointed to the Management Board in 2003 and, for example, bore key responsibility for development of Gerresheimer's important US and Chinese business.
The Supervisory Board is extremely sorry that Dr. Herberg is leaving the Management Board. He has developed Gerresheimer into a very successful global supplier for the pharma industry. The Supervisory Board therefore unanimously recommends that Dr. Herberg is elected to this body. We are pleased to have Uwe Röhrhoff as the new CEO at the head of the business from the summer. Mr Röhrhoff is ideal for this position and, thanks to his extraordinary specialist knowledge and industry expertise, enjoys a high level of trust among employees and customers, said Supervisory Board Chairman Gerhard Schulze.
Axel Herberg commented: The Gerresheimer Group is excellently positioned. The strategy to focus on pharma and healthcare with leading worldwide market positions has proven itself particularly during the crisis. With Uwe Röhrhoff, who I've worked with closely for almost twenty years, the company is in ideal hands.
In today's meeting of the Supervisory Board, Hans-Jürgen Wiecha (47), who has been with the company for ten years, including five years on the Management Board with responsibility for finance, was also appointed as Chief Financial Officer for a further five years.
Gerresheimer employs around 9,400 people in 40 locations in Europe, Americas and Asia. In the financial year 2009, worldwide sales totaled EUR1 billion. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma healthcare industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.
Contact Press Burkhard Lingenberg Director Corporate Communication Marketing Phone +49-211-6181-250 Fax +49-211-6181-241 e-mail firstname.lastname@example.org Contact Investor Relations Anke Linnartz Director Corporate Investor Relations Phone +49-211-6181-314 Fax +49-211-6181-121 e-mail email@example.com
SOURCE: Gerresheimer AG
CONTACT: Contact Press: Burkhard Lingenberg, Director CorporateCommunication Marketing, Phone +49-211-6181-250, Fax +49-211-6181-241,e-mail firstname.lastname@example.org . Contact Investor Relations: AnkeLinnartz, Director Corporate Investor Relations, Phone +49-211-6181-314,Fax +49-211-6181-121, e-mail email@example.com .